Meeting
2017 ASCO Annual Meeting
A randomised phase 2 study of 3 weekly cabazitaxel vs weekly paclitaxel chemotherapy in the first-line treatment of HER2 negative metastatic breast cancer.
Authors
Amit Bahl
University Hospitals Bristol NHS Foundation Trust - Bristol Haematology and Oncology Centre, Department of Oncology, Bristol, United Kingdom
Amit Bahl , Jeremy Braybrooke
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Other Breast Cancer Subtypes
Clinical Trial Registration Number
(Pending PRS review - due in next 2-5 days)
Citation
J Clin Oncol 35, 2017 (suppl; abstr TPS1122)
DOI
10.1200/JCO.2017.35.15_suppl.TPS1122
Abstract #
TPS1122
Poster Bd #
106a
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
The efficacy of first-line chemotherapy in endocrine-resistant hormone receptor-positive (HR+), human epidermal growth factor receptor 2- negative (HER2-) metastatic breast cancer (MBC).
First Author: Sudpreeda Chainitikun
Poster
2013 ASCO Annual Meeting
TAXYNERGY (NCT01718353): A randomized phase II trial examining an early switch from first-line docetaxel to cabazitaxel, or cabazitaxel to docetaxel, in men with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Emmanuel S. Antonarakis
Poster
2018 ASCO Annual Meeting
Phase II study of cabazitaxel as second-line treatment in patients with HER-2 negative metastatic breast cancer previously treated with taxanes.
First Author: Angelos Koutras
First Author: Ji-Yeon Kim